Abstract
Determination of feprazone and one of its metabolites in human plasma after high-performance liquid chromatographic or thin-layer chromatographic separation Two procedures suitable for pharmacokinetic routine analysis are described for the simultaneous determination of feprazone and one of its metabolites (DA 3505) in plasma samples. After extraction from acidified plasma feprazone and DA 3505 are determined by measuring UV absorbance after thin-layer chromatographic (TLC) separation (reversed-phase TLC plates; methanol—water—formic acid) or high-performance liquid chromatographic (HPLC) separation (silica gel column; hexane—tetrahydrofuran—acetic acid). Limits of detection are 0.1 μg feprazone per ml plasma and 0.2 μg of its metabolite per ml plasma using the HPLC method. Concentrations down to about 0.5 μg/ml plasma of both compounds can be determined using the TLC method.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
